A blog exploring pharmaceutical relationship marketing, emarketing and innovation with a focus on rare disorders.
SirenWired
The convergence of rare disease, digital communications, and pharmaceutical marketing communications

#SocPharm Tweetchat Transcript 10/3/2013

Posted by | 11:53pm on Wednesday, October 3, 2012

:
Welcome to the #socpharm chat with @ from Shire as moderator. Please say hi!

:
Please note that all tweets will be considered your personal views and not reflective of your employer or clients. #SocPharm

:
hi everyone! welcome to the #socpharm tweet chat

:
Hi All – Great to be here and looking forward to the conversation. Chuck #socpharm

:
Hi all, very excited to join #socpharm chat with @

:
Let’s start by talking about research and how patient leaders like @ @ and @ might play a role #socpharm

:
@, @ What topics are we looking forward to on tonite’s #socpharm chat? # #clinicaltrials #hcsm #epharma

:
Let’s start by talking abt clinical research & how pt leaders like @ @ @ might play role #SocPharm

:
Is anyone else having delays and issues with tweets not showing up in tweet stream? #SocPharm

:
yes, it’s slow tonight. maybe because of debates? #socpharm

:
With increase in social media patient leaders are taking big role in #clinicaltrial & research. #SocPharm

:
I bet u r right! RT @: yes, it’s slow tonight. maybe because of debates? #socpharm

:
Clinical Trials or Clinical/Medical “Research”? MT @: how patient leaders might play a role #socpharm

:
In #raredisease patient leaders are essential through entire process – from research through commercialization. #SocPharm

:
allowing patient leaders to curate and comment on research opportunities in a formal way could be invaluable #socpharm

:
@ Info/education from KOL/fellow patient especially valuable with uncertainty of a new therapy #socpharm

:
@ interesting idea, how could something like that work? #SocPharm

:
This can get political MT @: allowing patient leaders to curate & comment on research opportunities could be invaluable #socpharm

:
@ Patient leaders could perform a formal review of a protocol just as an ethics committee does #socpharm

:
@ That sounds so sensible. What are the barriers you foresee? #socpharm

:
How might patient leaders know about say JAK3 inhibitor role in Rheumatoid Arthritis? @ @ perform formal rev #socpharm

:
@ We are seeing a lot of patient leaders in #clinicaltrials and research for #raredisease #socpharm

:
A good example is @ who kickstarted a study with Mayo Clinic for her #raredisease SCAD http://t.co/8ulMc0op #socpharm

:
@ who would decide which pt leaders would be qualified to do this? And per @: how to keep it like Switzerland? #SocPharm

:
RT @: Program helps get diabetes under control | Richmond Times-Dispatch – http://t.co/T24f08wL #diabetes #dblog #socpharm #dsma

:
#SocPharm RT @ don’t think they’d need to have sophisticated knowledge abt MOAs but should understand what trial means to pts

:
@: we could start by requiring all trials posted to patient communities to undergo this review

:
@ @: Maybe I am being naive, but I think all patient leaders are “qualified” – its why they are leaders #socpharm

:
Good Evening my Name is Lisa and I’m a member of #THewalkinggallery & Society for Participatory Medicine. #socpharm

:
Patient groups most suitable to facilitate clinical trial recruitment @: @ who kickstarted a study #socpharm

:
@: don’t think they would need to have deep knowledge about MOAs, but should understand what a trial means to pts. #socpharm

:
@: welcome! Thanks for joining #socpharm. We’re talking pr leaders curating clinical trial info

:
Totally agree! MT @: Maybe I am being naive, but I think all patient leaders are “qualified” – its why they are leaders #socpharm

:
patients need to be able to talk to a real person to vet trial oppty. patient leaders are the natural choice #socpharm

:
Thx Eileen. Just got back from #MEDX. Dr. @ provided us with an amazing Conference w/Emphasis Patients. @: #socpharm

:
Without understanding MOA of a compound hard for anyone to provide useful clinical trial design info @ #SocPharm @

:
@: I work in #raredisease space so we are all about the patients/caregivers! And these r some amazing pts. #SocPharm

:
@: @ to be clear, not suggesting patient leaders contribute to study design #socpharm

:
Other #epatients in your Chat tonight. I”m seeing words like them, they. #S4PM #thewalkinggallery #MEDX G8 source 4 PT’s #socpharm

:
shall we move onto EHRs? Loved the video posted by @ #socpharm

:
while there is obvious value to accessing one’s own #EHR, there is a big missed oppty upstream #socpharm

:
@ @: do you have a link of the video to share? #SocPharm

:
Firms like @ and @ can use #EHR to help patients peek into their future #socpharm

:
@ @ http://t.co/mqBSUcQx #socpharm

:
Interesting stats show docs less positive about EHR compared to last year. http://t.co/XAdrPces #socpharm

:
@ I bet this helps to change behavior #SocPharm

:
Thx (EHRs) Can Save Lives:http://t.co/5CVUcrnv MT @: @ @: ink of the video. #socpharm

:
@: thanks, I’m a big fan of @ #SocPharm

:
when my son was inutero, he had nuchal fold that was “out of range” – marker for Downs. My doc, opened a book (!) to look up risk #socpharm

:
…would have been better to access analytics based on millions of EHRs #socpharm

:
patients deserve access to #bigdata and #EHR. we consume it all the time when looking up the weather, why not for healthcare #socpharm

:
Speaking of behavior change at Google ThinkHealth there was amazing co using video/animation to show how behavior impacts organs #SocPharm

:
Fully Agreed MT @ patients deserve access to #bigdata and #EHR.why not for healthcare #socpharm

:
Time is almost up. Anyone have any closing thoughts? #socpharm

:
“I think the biggest innovations of the 21st century will be at the intersection of biology and technology.” Jobs #socpharm

:
Thanks to those who joined in #SocPharm tonight and big thanks to @ for moderating. Will post transcript tomorrow.

:
thanks for having me! #socpharm

About Eileen O'Brien

Eileen has more than 16 years of digital healthcare marketing experience. She is an opinion leader on social media and biopharma, and has been invited to speak at industry conferences and quoted in publications.

View other posts from Eileen

Siren Interactive
  • Siren Interactive
  • Rare Disease Relationship Marketing Experts
  • 626 West Jackson Blvd, Suite 100
  • Chicago, IL 60661
  • 312.204.6700
  • 866.502.6714 (Toll Free)
  • www.sireninteractive.com